MAZE vs TRVI
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MAZE · Maze Therapeutics$34.19 ▲ 5.10%
TRVI · Trevi Therapeutics$14.33 ▲ 11.87%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MAZE +12.1%
- TRVI +22.8%
Head to head
| Metric | MAZE | TRVI |
|---|---|---|
| Price | $34.19 | $14.33 |
| Change today | ▲ 5.10% | ▲ 11.87% |
| Market cap | $1.90B | $2.04B |
| Return, 3 months | +25.3% | -19.5% |
| Return, year to date | -17.5% | +14.5% |
| Return, 1 year | +19.5% | +30.2% |
| P/E (TTM) | – | – |
| P/B | 4.2 | 6.3 |
| P/E percentile vs own 5y | 42nd | 10th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -32.8% | -44.7% |
| Gross margin | – | – |
| Operating margin | -728.1% | – |
| Net margin | -668.0% | – |
| Return on equity | -37.3% | -19.7% |
| Analyst target vs. price | +84.6% | +102.4% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 67 | 57 |
| 30-day volatility | 51.5% | 58.8% |
| Max drawdown, 1 year | -56.8% | -39.1% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TRVI is the largest of the group by market value.
- TRVI has returned the most over the past year.
- MAZE has been the calmest stock over the last 30 days.